Structure determination of the HIV‐1 envelope glycoprotein (Env) presented a number of
challenges, but several high‐resolution structures have now become available. In 2013 …

We describe the development and potential use of various designs of recombinant HIV‐1
envelope glycoprotein trimers that mimic the structure of the virion‐associated spike, which …

The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) has resulted in more than 28,000,000 infections and 900,000 …

Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)
coronaviruses (CoVs) are zoonotic pathogens with high fatality rates and pandemic …

The envelope glycoprotein trimer (Env) on the surface of HIV-1 recognizes CD4+ T cells and
mediates viral entry. During this process, Env undergoes substantial conformational …

Abstract HIV-1 envelope glycoprotein (Env) is the sole target for broadly neutralizing
antibodies (bnAbs) and the focus for design of an antibody-based HIV vaccine. The Env …

The HIV-1 envelope glycoprotein trimer is covered by an array of N-linked glycans that
shield it from immune surveillance. The high density of glycans on the trimer surface …

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of
the Coronavirus disease (COVID-19) pandemic, has so far resulted in more than 1.1 M …

A preventive HIV-1 vaccine should induce HIV-1–specific broadly neutralizing antibodies
(bnAbs). However, bnAbs generally require high levels of somatic hypermutation (SHM) to …

INTRODUCTION A major goal of HIV-1 vaccine development is the design of immunogens
that induce broadly neutralizing antibodies (bnAbs). However, vaccination of humans has …